lobbying_activities: 2426123

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2426123 83aa9440-05dd-4527-b8f2-4a0db34318e9 Q1 MEHLMAN CONSULTING, INC. 284950 AARP, INC. 2020 first_quarter PHA S.1895 - Lower Health Care Costs Act including issues relating to drug pricing Older Americans Reauthorization Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019. House prescription drug price transparency legislation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-04-15T12:24:52.653000-04:00